Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ustekinumab.

Literature DB >> 19404310

Ustekinumab.

Kristian Reich, Uma Yasothan, Peter Kirkpatrick.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2009 PMID： 19404310 DOI： 10.1038/nrd2878

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

× No keyword cloud information.

18 in total

Review 1. Psoriasis.

Authors: Michael P Schön; W-Henning Boehncke
Journal: N Engl J Med Date: 2005-05-05 Impact factor: 91.245

2. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder.

Authors: K Hong; A Chu; B R Lúdvíksson; E L Berg; R O Ehrhardt
Journal: J Immunol Date: 1999-06-15 Impact factor: 5.422

3. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey.

Authors: L Dubertret; U Mrowietz; A Ranki; P C M van de Kerkhof; S Chimenti; T Lotti; G Schäfer
Journal: Br J Dermatol Date: 2006-10 Impact factor: 9.302

Review 4. Psoriasis: emerging therapeutic strategies.

Authors: Alice B Gottlieb
Journal: Nat Rev Drug Discov Date: 2005-01 Impact factor: 84.694

Review 5. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.

Authors: Kristian Reich; Rodney Sinclair; Graeme Roberts; Christopher E M Griffiths; Maggie Tabberer; Jonathan Barker
Journal: Curr Med Res Opin Date: 2008-03-19 Impact factor: 2.580

Review 6. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.

Authors: J Schmitt; Z Zhang; G Wozel; M Meurer; W Kirch
Journal: Br J Dermatol Date: 2008-07-09 Impact factor: 9.302

7. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Authors: Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich
Journal: Lancet Date: 2008-05-17 Impact factor: 79.321

Review 8. Interleukin-12, interleukin-23, and psoriasis: current prospects.

Authors: Dorothea C Torti; Steven R Feldman
Journal: J Am Acad Dermatol Date: 2007-08-15 Impact factor: 11.527

9. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany.

Authors: M Augustin; K Krüger; M A Radtke; I Schwippl; K Reich
Journal: Dermatology Date: 2008-03-04 Impact factor: 5.366

Review 6. Emerging role of targeting macrophages in rheumatoid arthritis: Focus on polarization, metabolism and apoptosis.

Authors: Xuezhi Yang; Yan Chang; Wei Wei
Journal: Cell Prolif Date: 2020-06-12 Impact factor: 6.831

6 in total

Ustekinumab.

Review 1. Psoriasis.

2. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder.

3. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey.

Review 4. Psoriasis: emerging therapeutic strategies.

Review 5. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.

Review 6. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.

7. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Review 8. Interleukin-12, interleukin-23, and psoriasis: current prospects.

9. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany.

10. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.

Review 1. New insights in the immunologic basis of psoriasis.

2. Psoriasis market.

Review 3. Managing macrophages in rheumatoid arthritis by reform or removal.

Review 4. The pathophysiological role of dendritic cell subsets in psoriasis.

Review 5. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis.

Review 6. Emerging role of targeting macrophages in rheumatoid arthritis: Focus on polarization, metabolism and apoptosis.